Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel polymeric micelles plus ivonescimab in relapsed/refractory small cell lung cancer
ChiCTR2600129318Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2026
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and ivonescimab in small cell lung cancer (SCLC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
paclitaxelivonescimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600129318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129318.